Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VERTEX PHARMACEUTICALS

(VRTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
190.11(c) 186.94(c) 205(c) 204.45(c) 203.81(c) Last
2 801 959 3 988 612 7 044 745 3 378 098 2 641 589 Volume
+3.55% -1.67% +9.66% -0.27% -0.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7 503 M - -
Net income 2021 2 293 M - -
Net cash position 2021 8 318 M - -
P/E ratio 2021 23,1x
Yield 2021 -
Sales 2022 8 212 M - -
Net income 2022 2 975 M - -
Net cash position 2022 12 053 M - -
P/E ratio 2022 17,7x
Yield 2022 -
Capitalization 51 819 M 51 819 M -
EV / Sales 2021 5,80x
EV / Sales 2022 4,84x
Nbr of Employees 3 400
Free-Float 99,8%
More Financials
Company
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination... 
More about the company
Ratings of Vertex Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VERTEX PHARMACEUTICALS
12/03PUMP / DUMP #13 : This week's gainers and losers
12/02RBC Lifts Price Target on Vertex Pharmaceuticals to $265 From $250, Citing 'Strong' Pro..
MT
12/01Equities Led Higher Midday by Energy, Financials Following BioNTech CEO Comment on Vacc..
MT
12/01MIDDAY REPORT : US Stocks Led Higher by Energy, Financials Following BionTech CEO Comment ..
MT
12/01Vertex Pharmaceuticals Up Over 7%, Best Performer in The S&P 500 and Nasdaq 100 So Far ..
DJ
12/01Vertex's Kidney Disorder Drug VX-147 Reduces Proteinuria in Phase 2 Study
MT
12/01Vertex Pharmaceuticals to Advance VX-147 Kidney Drug After Phase 2 Study
DJ
12/01Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal ..
BU
12/01Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2 Study of VX..
CI
11/22NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
11/22Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/ele..
AQ
11/19Vertex Pharmaceuticals' Combination Therapy for Cystic Fibrosis Gets Spanish Approval f..
MT
11/19Vertex Announces Reimbursement Agreement in Spain for KAFTRIO« (ivacaftor/tezacaftor/el..
BU
11/19BMO Capital Starts Vertex Pharmaceuticals at Market Perform With $202 Price Target
MT
11/18Piper Sandler Downgrades Vertex Pharmaceuticals to Neutral From Overweight, Sets $218 P..
MT
More news
News in other languages on VERTEX PHARMACEUTICALS
12/03PUMP / DUMP #40 : Les Tops & Flops de la semaine
12/01Electrocomponents und Dechra Pharma kommen in FTSE 100
12/01Les actions sont portées à la hausse en milieu de journée par l'énergie et les services..
12/01RAPPORT DE LA MI-JOURNÉE : Les actions américaines sont tirées vers le haut par l'énergie ..
12/01Le VX-147 de Vertex, un médicament contre les troubles rénaux, réduit la protéinurie da..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS
More recommendations
Chart VERTEX PHARMACEUTICALS
Duration : Period :
Vertex Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 203,81 $
Average target price 258,17 $
Spread / Average Target 26,7%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS-13.76%51 819
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
BEIGENE, LTD.36.22%32 284